Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022-2023.

IF 6.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jonas A Linck, Christian Michels, Annekatrin Schwanstecher, Imke Schamarek, Dorothea Hinsch, Christoph Terkamp, Clemens F Ringel, Annika Hoyer, David J F Holstein, Marcus Altmeier, Andreas Holstein
{"title":"Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022-2023.","authors":"Jonas A Linck, Christian Michels, Annekatrin Schwanstecher, Imke Schamarek, Dorothea Hinsch, Christoph Terkamp, Clemens F Ringel, Annika Hoyer, David J F Holstein, Marcus Altmeier, Andreas Holstein","doi":"10.1177/15209156251380863","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To obtain clinical features of diabetic ketoacidosis (DKA) in adults leading to hospital admission. <b><i>Methods:</i></b> Multicenter observational study investigating DKAs treated in five German tertiary hospitals between 2022 and 2023. <b><i>Results:</i></b> A total of 179 patients with 203 episodes of DKA were registered: 64% of cases in pre-existing type 1 diabetes mellitus (T1DM), 14% in new-onset T1DM, 14% in pre-existing type 2 diabetes mellitus (T2DM), 3% in new-onset T2DM, 6% in latent autoimmune diabetes in adults, and 6% in pancreatogenic diabetes. Seven cases of SGLT 2 inhibitor (SGLT 2-I)-associated euglycemic DKA (EDKA) were encountered. In pre-existing T1DM, DKA occurred despite continuous glucose monitoring in 51% of patients and insulin pumps or automated insulin delivery in 24%. Only 21% of individuals with T1DM were in possession of ketone test and only 6% applied ketone testing. In total, 71% of patients with pre-existing T1DM experienced recurrent episodes of DKA. Suboptimal adherence to diabetes therapy was the most common triggering factor for DKA in known T1DM (56%), whereas infections contributed most in pre-existing T2DM (32%). The entirety of patients pretreated with SGLT2-Is and particularly also those with SGLT2-I associated EDKA were not educated concerning sick-day-rules. The inpatient mortality risk of DKA was 2.3% and restricted to multimorbid patients with known T2DM. <b><i>Conclusions:</i></b> The clinical and etiological pattern of DKA is heterogeneous. Patients with pre-existing T1DM showed educational deficits concerning diagnostic and therapeutic measures to prevent DKA. Individuals with recurrent episodes of DKA require individual therapeutic concepts within the multidisciplinary diabetes care team. Emphasizing sick-day-rules in patients being treated with SGLT 2-Is is indispensable to prevent EDKA. Individuals with pre-existing T2DM represent a vulnerable group with severe comorbidities and high mortality risk due to DKA.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156251380863","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To obtain clinical features of diabetic ketoacidosis (DKA) in adults leading to hospital admission. Methods: Multicenter observational study investigating DKAs treated in five German tertiary hospitals between 2022 and 2023. Results: A total of 179 patients with 203 episodes of DKA were registered: 64% of cases in pre-existing type 1 diabetes mellitus (T1DM), 14% in new-onset T1DM, 14% in pre-existing type 2 diabetes mellitus (T2DM), 3% in new-onset T2DM, 6% in latent autoimmune diabetes in adults, and 6% in pancreatogenic diabetes. Seven cases of SGLT 2 inhibitor (SGLT 2-I)-associated euglycemic DKA (EDKA) were encountered. In pre-existing T1DM, DKA occurred despite continuous glucose monitoring in 51% of patients and insulin pumps or automated insulin delivery in 24%. Only 21% of individuals with T1DM were in possession of ketone test and only 6% applied ketone testing. In total, 71% of patients with pre-existing T1DM experienced recurrent episodes of DKA. Suboptimal adherence to diabetes therapy was the most common triggering factor for DKA in known T1DM (56%), whereas infections contributed most in pre-existing T2DM (32%). The entirety of patients pretreated with SGLT2-Is and particularly also those with SGLT2-I associated EDKA were not educated concerning sick-day-rules. The inpatient mortality risk of DKA was 2.3% and restricted to multimorbid patients with known T2DM. Conclusions: The clinical and etiological pattern of DKA is heterogeneous. Patients with pre-existing T1DM showed educational deficits concerning diagnostic and therapeutic measures to prevent DKA. Individuals with recurrent episodes of DKA require individual therapeutic concepts within the multidisciplinary diabetes care team. Emphasizing sick-day-rules in patients being treated with SGLT 2-Is is indispensable to prevent EDKA. Individuals with pre-existing T2DM represent a vulnerable group with severe comorbidities and high mortality risk due to DKA.

成人糖尿病酮症酸中毒的当前临床特征:德国多中心研究2022-2023。
目的:了解成人糖尿病酮症酸中毒(DKA)致住院的临床特点。方法:对2022 - 2023年间在德国5家三级医院治疗的dka进行多中心观察研究。结果:共有179例DKA患者203次发作:64%为既往1型糖尿病(T1DM), 14%为新发T1DM, 14%为既往2型糖尿病(T2DM), 3%为新发T2DM, 6%为成人潜伏性自身免疫性糖尿病,6%为胰源性糖尿病。7例SGLT 2抑制剂(SGLT 2- i)相关的血糖DKA (EDKA)。在已有的T1DM患者中,51%的患者在持续血糖监测和24%的患者在胰岛素泵或自动胰岛素输送的情况下仍发生DKA。只有21%的T1DM患者进行了酮类检测,只有6%的患者进行了酮类检测。总的来说,71%的已有T1DM患者经历了复发性DKA发作。对糖尿病治疗的依从性不佳是已知T2DM患者DKA最常见的触发因素(56%),而感染在已存在T2DM患者中最常见(32%)。所有预先接受SGLT2-Is治疗的患者,特别是那些与SGLT2-I相关的EDKA患者,没有接受有关病假规则的教育。DKA的住院死亡率风险为2.3%,且仅限于已知T2DM的多病患者。结论:DKA的临床和病因具有异质性。已有T1DM的患者在预防DKA的诊断和治疗措施方面存在教育缺陷。反复发作DKA的个体需要在多学科糖尿病护理团队中有个性化的治疗理念。在接受sglt2 - is治疗的患者中强调病假规则对于预防EDKA是必不可少的。患有T2DM的个体是一个易受影响的群体,有严重的合并症和DKA导致的高死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信